Bisphosphonate chemotherapy is commonly used in the treatment of bone diseases such as osteoporosis, Paget disease, and multiple myeloma and to limit bone pain and hypercalcemia associated with malignant metastatic bone lesions. The introduction of bisphosphonate therapy has improved the quality of life in a vast majority of patients. However, since 2003 a growing number of reports have described necrotic bone lesions (bisphosphonate—associated Osteonecrosis of the jaw [BR-ONJ]) a bone lesion affecting maxillofacial bones in patients who have received high dosage chemotherapy with intravenous bisphosphonate therapy especially when the patient undergoes subsequent dental procedures.
Sequential removal of sequestra as required seems to be the current conservative approach, but if large-volume debridement becomes necessary, removal of the bone sequestrum with minimal epithelial manipulation associated with topical and systemic antibiotics seem to be the treatment modality of choice. In our case, surgical salvage was performed successfully for BR-ONJ. Our experience indicates that with appropriate technique, primary surgical treatment may offer benefit to selected patients with BR-ONJ.
Osteonecrosis Maxilla Bisphosphonate
Woo SB, Hellstein JW, Kalmar JR (2006) Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 144(10):753–61. Review. Erratum in: Ann Intern Med. 2006 145(3):235Google Scholar
Ruggiero SL, Fantasia J, Carlson E (2006) Bisphosphonate related osteonecrosis of the jaw: background and guidelines for diagnosis, staging and management. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 102:433–440CrossRefPubMedGoogle Scholar
Marx RE, Sawatari Y, Fortin M, Broumand V (2005) Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 63:1567–1575CrossRefPubMedGoogle Scholar
Nancollas GH, Tang R, Phipps RJ, Henneman Z, Gulde S, Wu W, Mangood RG et al (2005) Novel insights into actions of bisphosphonates on bone differences in interactions with hydroxyapatite. Bone Google Scholar
Vaananen K (2005) Mechanism of osteoclast mediated bone resorption—rationale for the design of new therapeutics. Adv Drug Deliv Rev 57:959–971CrossRefPubMedGoogle Scholar
Wang J, Goodger NM, Pogrel MA (2003) Osteonecrosis of the jaws associated with cancer chemotherapy. J Oral Maxillofac Surg 61:1104–1107CrossRefPubMedGoogle Scholar
Marx RE (2003) Pamidronate (Aredia) and zolendronate (Zometa) induced avascular necrosis of the jaws a growing epidemic. J Oral Maxillofac Surg 61:1115–1117CrossRefPubMedGoogle Scholar
Miglioratti CA (2003) Bisphosphonates and oral cavity avascular bone necrosis. J Clin Oncol 21:4253–4254CrossRefGoogle Scholar
Hellstein JW, Marek CL, Pharm BS (2005) Bisphosphonate osteochemonecrosis (bis-phossy jaw) is this phossy jaw of the 21st century? J Oral Maxillofac Surg 63:682–689CrossRefPubMedGoogle Scholar
Hellstein J, Fielding C (2005) Bisphosphonate osteochemonecrosis clinical findings and treatment theories may relate to a possible analogy with “phossy” jaw. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 100:189–190CrossRefGoogle Scholar
Ruggiero SL, Mehrotra B, Rosenberg T, Engroff SL (2004) Osteonecrosis of the jaws associated with the use of bisphosphonates a review of 63 cases. J Oral Maxillofac Surg 62:527–534CrossRefPubMedGoogle Scholar